Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial
Randomized Controlled Trial
[키워드] 1:1
24 hour
absolute difference
acute illness
adjusted
adjusted relative risk
Adverse
adverse event
age
all-cause hospitalization
Brazil
Canada
clinical
clinical trial
collected
conducted
COVID-19
COVID-19 progression
Critical
death
diarrhea
Disease progression
duration of follow-up
Effect
Efficacy
end point
evaluate
event
favor
Follow-up
high-risk patient
Hospitalization
increased risk
infected with SARS-CoV-2
interim analysis
intravenous
intravenous dose
Latinx
management
mechanical ventilation
median age
Mild
Moderate COVID-19
neutralizing antibody
outcome
Patient
patients randomized
patients with COVID-19
Placebo
Pneumonia
Prevent
Primary outcome
progression
proportion
Randomized
reduced
requiring supplemental oxygen
risk
risk factor
SARS-CoV-2 variant
secondary outcome
severe disease
significantly
Sotrovimab
Spain
statistically significant
Support
symptomatic
tested
the median
those with comorbidity
Treatment
treatment group
[DOI] 10.1001/jama.2022.2832 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1001/jama.2022.2832 PMC 바로가기 [Article Type] Randomized Controlled Trial